Jason M Broderick

Keytruda (pembrolizumab) was granted an accelerated approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients who have unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

Keytruda (pembrolizumab) was granted an approval by the Food and Drug Administration (FDA) to treat some patients with locally advanced or metastatic urothelial carcinoma.

Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/refractory follicular lymphoma who had at least two therapies beforehand, according to Bayer, the manufacturer of the drug.

The Food and Drug Administration has granted approval for a combination therapy with Keytruda (pembrolizumab) for patients with non–small cell lung cancer.

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The Food and Drug Administration has granted accelerated approval for durvalumab for treatment of patients with bladder cancer.

The Food and Drug Administration has granted accelerated approval to Alunbrig (brigatinib) for metastatic ALK-positive non-small cell lung cancer (NSCLC).

The Food and Drug Administration has approved Rydapt (midostaurin) for acute myeloid leukemia (AML).

The Food and Drug Administration (FDA) has approved Stivarga as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who have previously received Nexavar.

Ibrance gained full FDA approval for the treatment of some patients with breast cancer.

All members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted to approve Rituxan for the treatment of some blood cancers.

The FDA has approved Zejula (niraparib) for treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the maintence setting.

Bavencio (avelumab), a PD-L1-inhibitor, gained approval by the Food and Drug Administration (FDA) for some patients with Merkel cell carcinoma.

Kisqali (ribociclib), a CDK 4/6 inhibitor, gained approval from the Food and Drug Administration (FDA) for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

The supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) is still under review by the Food and Drug Administration (FDA) to treat MSI-H cancer.

In a recent study, Blincyto (blinatumomab) had longer survival rates than standard chemotherapy for certain patients with ALL.

Kyprolis (carfilzomib) plus dexamethasone improved overall survival for patients with relapsed or refractory multiple myeloma.

Xermelo (telotristat ethyl) was approved by the Food and Drug Administration (FDA) to treat diarrhea in patients with carcinoid syndrome.

The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug.

The FDA granted Zykadia a priority review for the frontline treatment of some patients with lung cancer.

Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way to more personalized prostate cancer care.

The Food and Drug Administration (FDA) approved Revlimid (lenalidomide) for maintenance therapy for some patients with multiple myeloma.

In a recent phase 3 trial, Lynparza improved progression-free survival in patients with BRCA-positive, HER2-negative breast cancer.

A supplemental biologics license application was filed for Blincyto to be approved for certain patients with ALL.

A recent phase 3 trial showed that treatment with Lenvima is noninferior to standard treatment for patients with unresectable liver cancer.

Opdivo is showing benefit for patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), according to a recent trial.

Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.

The clinical hold on pacritinib was recently lifted by the US Food and Drug Administration (FDA).

Stivarga was granted a priority review by the FDA to treat certain patients with liver cancer in the second line setting.

Adding Xtandi to Zytiga and prednisone did not improve progression-free survival for patients with metastatic castration-resistant prostate cancer, according to a recent study.